• 1
    Pettit GR,Singh SB,Hamel E,Lin CM,Alberts DS,Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 20911.
  • 2
    Olmsted JB,Borisy GG. Microtubules. Annu Rev Biochem 1973; 42: 50740.
  • 3
    Kanthou C,Greco O,Stratford A,Cook I,Knight R,Benzakour O,Tozer G. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 2004; 165: 140111.
  • 4
    Bohle AS,Leuschner I,Kalthoff H,Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 2000; 87: 83843.
  • 5
    Nabha SM,Mohammad RM,Dandashi MH,Coupaye-Gerard B,Aboukameel A,Pettit GR,Al-Katib AM. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 2002; 8: 273541.
  • 6
    Boehle AS,Sipos B,Kliche U,Kalthoff H,Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001; 71: 165765.
  • 7
    Beauregard DA,Hill SA,Chaplin DJ,Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61: 681115.
  • 8
    Tozer GM,Prise VE,Wilson J,Cemazar M,Shan S,Dewhirst MW,Barber PR,Vojnovic B,Chaplin DJ. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 641322.
  • 9
    Vincent L,Kermani P,Young LM,Cheng J,Zhang F,Shido K,Lam G,Bompais-Vincent H,Zhu Z,Hicklin DJ,Bohlen P,Chaplin DJ, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 29923006.
  • 10
    Grosios K,Loadman PM,Swaine DJ,Pettit GR,Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20: 22933.
  • 11
    Siemann DW,Mercer E,Lepler S,Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 16.
  • 12
    Bilenker JH,Flaherty KT,Rosen M,Davis L,Gallagher M,Stevenson JP,Sun W,Vaughn D,Giantonio B,Zimmer R,Schnall M,O'Dwyer PJ. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005; 11: 152733.
  • 13
    Cobb MH,Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995; 270: 148436.
  • 14
    Kang CD,Yoo SD,Hwang BW,Ahn BK,Kim SH,Chung BS,Jhun BH,Yoo MA. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res 2000; 24: 52734.
  • 15
    Gupta K,Kshirsagar S,Li W,Gui L,Ramakrishnan S,Gupta P,Law PY,Hebbel RP. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999; 247: 495504.
  • 16
    Xia Z,Dickens M,Raingeaud J,Davis RJ,Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 132631.
  • 17
    Ip YT,Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)—from inflammation to development. Curr Opin Cell Biol 1998; 10: 20519.
  • 18
    Nebreda AR,Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000; 25: 25760.
  • 19
    Kummer JL,Rao PK,Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997; 272: 204904.
  • 20
    MacKeigan JP,Collins TS,Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 389536.
  • 21
    Zelivianski S,Spellman M,Kellerman M,Kakitelashvilli V,Zhou XW,Lugo E,Lee MS,Taylor R,Davis TL,Hauke R,Lin MF. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003; 107: 47885.
  • 22
    Stadheim TA,Xiao H,Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 2001; 61: 153340.
  • 23
    Seidman R,Gitelman I,Sagi O,Horwitz SB,Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001; 268: 8492.
  • 24
    Deacon K,Mistry P,Chernoff J,Blank JL,Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 2003; 14: 207187.
  • 25
    Kanthou C,Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 20609.
  • 26
    Jaffe EA,Nachman RL,Becker CG,Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 274556.
  • 27
    Lieuvin A,Labbe JC,Doree M,Job D. Intrinsic microtubule stability in interphase cells. J Cell Biol 1994; 124: 98596.
  • 28
    Hadfield JA,Ducki S,Hirst N,McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003; 5: 30925.
  • 29
    Honore S,Kamath K,Braguer D,Wilson L,Briand C,Jordan MA. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol Cancer Ther 2003; 2: 130311.
  • 30
    Kawasaki H,Morooka T,Shimohama S,Kimura J,Hirano T,Gotoh Y,Nishida E. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 1997; 272: 1851821.
  • 31
    Shtil AA,Mandlekar S,Yu R,Walter RJ,Hagen K,Tan TH,Roninson IB,Kong AN. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 1999; 18: 37784.
  • 32
    Stone AA,Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254: 11019.
  • 33
    Subbaramaiah K,Hart JC,Norton L,Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000; 275: 1483845.
  • 34
    Faisal A,Kleiner S,Nagamine Y. Non-redundant role of Shc in Erk activation by cytoskeletal reorganization. J Biol Chem 2004; 279: 320211.
  • 35
    Lin CM,Ho HH,Pettit GR,Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989; 28: 698491.
  • 36
    Tozer GM,Kanthou C,Baguley BC. Disrupting tumour blood vessels. Nature Rev Cancer 2005; 5: 42335.
  • 37
    Dziba JM,Marcinek R,Venkataraman G,Robinson JA,Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002; 12: 106370.
  • 38
    Rustin GRS,Galbraith SM,Anderson H,Stratford M,Folkes LK,Sena L,Gumbrell L,Price PM. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncology 2003; 21: 281522.
  • 39
    Hill SA,Sampson LE,Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995; 63: 11923.
  • 40
    Birrell M,Hele D,McCluskie K,Webber S,Foster M,Belvisi MG. Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. Eur Respir J 2000; 16: 94750.
  • 41
    Branger J,van den Blink B,Weijer S,Madwed J,Bos CL,Gupta A,Yong CL,Polmar SH,Olszyna DP,Hack CE. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 40707.
  • 42
    Jackson JR,Bolognese B,Hillegass L,Kassis S,Adams J,Griswold DE,Winkler JD. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998; 284: 68792.